Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
02/2003
02/06/2003WO2003010297A1 Probiotic bifidobacterium strains
02/06/2003WO2003010286A2 Nucleic acids, polypeptides, and methods for modulating apoptosis
02/06/2003WO2003010164A1 Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors
02/06/2003WO2003009867A1 Use of biologically active hiv-1 tat, fragments or derivates thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
02/06/2003WO2003009847A1 Substituted piperidines as modulators of the melanocortin receptor
02/06/2003WO2003009841A1 Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine
02/06/2003WO2003009809A2 Cancer treatment with gö6976 and its related compounds
02/06/2003WO2003009807A2 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
02/06/2003WO2003009800A1 Sustained-release therapeutic bioadhesive systems
02/06/2003WO2002079146A3 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
02/06/2003WO2002067851A3 Method for treating fibrotic diseases or other indications iiic
02/06/2003WO2002061110A3 Nucleic acid derivatives
02/06/2003WO2002059112A3 Pyrazole compounds useful as protein kinase inhibitors
02/06/2003WO2002048134A3 Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists
02/06/2003WO2002020722A3 Methods and compositions for in vitro targeting
02/06/2003WO2002010217A9 Endothelial cell expression patterns
02/06/2003WO2002010137A9 Indazole derivatives as jnk inhibitors
02/06/2003WO2002002095A3 Compositions for treating bacterial infections containing oxazolidinone compound, sulbactam and an ampicillin
02/06/2003US20030028639 Access control system
02/06/2003US20030027852 Substituted pyrrolidine-2,3,4-trione 3-oxime deerivatives which are active as NMDA receptor antagonists
02/06/2003US20030027851 Readily soluble crystal modification; specific X-ray diffraction pattern obtained with a focusing Debye-Scherrer beam and Cu-K alpha 1-radiation
02/06/2003US20030027845 Ether derivatives useful as inhibitors of PDE4 isozymes
02/06/2003US20030027840 Estrogen receptor modulators
02/06/2003US20030027824 Pyrazolopyrimidinones for the treatment of female sexual dysfunction
02/06/2003US20030027820 Method for treating fibrotic diseases or other indications V
02/06/2003US20030027795 N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists
02/06/2003US20030027794 N-heterocyclic derivatives as NOS inhibitors
02/06/2003US20030027767 To cause apoptosis in colon cancer and prostate cancer cells
02/06/2003US20030027253 Nucleotides equences codin polypeptide for use in the treatment of cancer
02/06/2003US20030027232 Novel compounds
02/06/2003US20030027211 Fetuin-MGP-mineral complex in serum
02/06/2003US20030027164 Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain
02/06/2003US20030027158 Novel nucleic acid sequences encoding human breast tumor-associated protein 47-like polypeptides
02/06/2003CA2857312A1 Nucleic acids, polypeptides, and methods for modulating apoptosis using deoxyhypusine synthase (dhs)
02/06/2003CA2454822A1 Nucleic acids, polypeptides, and methods for modulating apoptosis using apoptosis-specific eif-5a
02/06/2003CA2454803A1 Probiotic bifidobacterium strains
02/06/2003CA2452328A1 Substituted piperidines as modulators of the melanocortin receptor
02/06/2003CA2452259A1 Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors
02/06/2003CA2452159A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
02/05/2003WO2002014280A1 Piperidine derivatives and drugs containing these derivatives as the active ingredient
02/05/2003EP1281401A2 The medical effect of Jojoba oil
02/05/2003EP1280908A2 Treatment of neoplasia / transformation using pituitary tumor transforming gene 2
02/05/2003EP1280907A2 Method of modulating activation of lymphocytes via modulation of pituitary tumor transforming gene, related screeining methods
02/05/2003EP1280906A2 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg)
02/05/2003EP1280820A2 Anti-inflammatory compounds and uses thereof
02/05/2003EP1280816A1 19-norbufalin derivatives, their preparation and pharmaceutical compositions containing them
02/05/2003EP1280805A1 Novel imidazotriazinones and the use thereof
02/05/2003EP1280799A1 Ortho-substituted anthranilic acid amides and their use as medicaments
02/05/2003EP1280798A1 Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them
02/05/2003EP1280777A1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
02/05/2003EP1280776A1 Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis
02/05/2003EP1280774A1 Substituted indoles as parp inhibitors
02/05/2003EP1280555A2 Treatment of congestive heart failure with a composition comprising a diuretic agent and a vasopressin antagonist
02/05/2003EP1280546A1 Method and composition for the treatment of angiogenesis
02/05/2003EP1280486A1 Minimizing adverse experience associated with oxybutynin therapy
02/05/2003EP1037868B1 $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS
02/05/2003CN1395581A Recombinant antibodies to human IL-1 beta
02/05/2003CN1395566A Corticotropin releasing factor antagonists
02/05/2003CN1395558A Substituted benzoylguanidines, method for their production, their use as medicament or diagnostic agent and mediciment containing same
02/05/2003CN1394855A Substituted heterocyclic compound
02/04/2003US6515117 C-aryl glucoside SGLT2 inhibitors and method
02/04/2003US6515025 Use of ethynyl alanine amino diol compounds to inhibit enzymatic conversion of angiotensinogen to angiotensin I
02/04/2003US6515002 Compounds and compositions for treating C1s-mediated diseases and conditions
02/04/2003US6514983 Inhibitors of the nucleic enzyme poly(adenosine 5'-diphospho-ribose)polymerase
02/04/2003US6514977 For treating p38 kinase mediated disorders
02/04/2003US6514975 Anti-inflammatory piperazinyl-benzyl-tetrazole derivatives and intermediates thereof
02/04/2003US6514934 For treating sexual dysfunctions in males and females
02/04/2003CA2271478C Tissue specific expression of retinoblastoma protein
02/04/2003CA2178479C Chroman derivatives
01/2003
01/30/2003WO2003008444A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
01/30/2003WO2003008443A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
01/30/2003WO2003008410A2 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression
01/30/2003WO2003008409A1 Quinoline derivatives and their use as tyrosine kinase inhibitors
01/30/2003WO2003008407A2 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
01/30/2003WO2003008384A1 Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands
01/30/2003WO2003008371A1 Substituted 4-aminocyclohexanol derivatives
01/30/2003WO2003008370A1 Substituted 4-aminocyclohexanols
01/30/2003WO2003008365A2 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
01/30/2003WO2003007993A1 Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor
01/30/2003WO2003007954A2 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
01/30/2003WO2003007930A2 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
01/30/2003WO2003007686A2 Use of copper chelators to inhibit the inactivation of protein c
01/30/2003WO2002060449A3 Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates
01/30/2003WO2002051435A3 New therapeutic uses of smr1 peptides
01/30/2003WO2002047679A8 Nonpeptide agonists and antagonists of vasopressin receptors
01/30/2003WO2002043786A3 Uses for medical devices having a lubricious, nitric oxide-releasing coating for the therapy of vascular disorders
01/30/2003WO2002018583A3 Modified polypeptides stabilized in a desired conformation and methods for producing same
01/30/2003WO2002018375A1 Quinazolines, medicaments, which contain these compounds and which are effective as tyrosine kinase inhibitors, their use, and methods for the production thereof
01/30/2003WO2002018351A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
01/30/2003WO2002005795B1 Pharmaceutical combinations for treatment and prevention of diabetes mellitus
01/30/2003WO2002002634A3 Human extracellular matrix and cell adhesion polypeptides
01/30/2003WO2002000617A3 Selective androgen receptor modulators and methods for their identification, design and use
01/30/2003WO2001090359A3 G-protein coupled receptors
01/30/2003US20030023100 For therapy of inflammatory and allergic reactions, drug or alcohol abuse, diarrhoea, gastritis, ulcers, cardiovascular diseases, urinary incontinence, depressions, states of shock, migranes, narcolepsy, overweight, asthma, glaucoma, etc.
01/30/2003US20030023034 p27 (Kip1) -FKBP-12 protein complexes
01/30/2003US20030022939 4-Fluoro-N- indan-2-yl benzamide and its use as a pharmaceutical
01/30/2003US20030022935 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents
01/30/2003US20030022929 Method of using soluble epoxide hydrolase inhibitors
01/30/2003US20030022925 5-(dialkylamine)alkoxy)-1H-pyrazole derivatives
01/30/2003US20030022909 Use of methylnaltrexone to treat immune suppression